Invesco
VRDN icon

Invesco’s Viridian Therapeutics VRDN Stock Holding History

Invesco’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.85M Sell
100,895
-51,701
-34% -$833K ﹤0.01% 2620
2026
Q1 		$2.98M Sell
152,596
-30,872
-17% -$917K ﹤0.01% 2379
2025
Q4 		$5.71M Buy
183,468
+102,676
+127% +$2.82M ﹤0.01% 2186
2025
Q3 		$1.74M Buy
80,792
+18,575
+30% +$335K ﹤0.01% 2672
2025
Q2 		$870K Buy
62,217
+14,446
+30% +$196K ﹤0.01% 2907
2025
Q1 		$644K Buy
47,771
+14,672
+44% +$250K ﹤0.01% 3051
2024
Q4 		$635K Buy
33,099
+12,350
+60% +$269K ﹤0.01% 3133
2024
Q3 		$472K Buy
20,749
+178
+0.9% +$2.91K ﹤0.01% 3259
2024
Q2 		$268K Buy
20,571
+1,841
+10% +$25.5K ﹤0.01% 3538
2024
Q1 		$328K Sell
18,730
-126,035
-87% -$2.44M ﹤0.01% 3499
2023
Q4 		$3.15M Buy
144,765
+116,932
+420% +$1.85M ﹤0.01% 2456
2023
Q3 		$427K Buy
27,833
+8,394
+43% +$160K ﹤0.01% 3277
2023
Q2 		$462K Buy
19,439
+789
+4% +$20.2K ﹤0.01% 3283
2023
Q1 		$474K Sell
18,650
-175,887
-90% -$5.64M ﹤0.01% 3282
2022
Q4 		$5.68M Sell
194,537
-29,779
-13% -$686K ﹤0.01% 2181
2022
Q3 		$4.6M Buy
224,316
+213,278
+1,932% +$3.83M ﹤0.01% 2272
2022
Q2 		$128K Buy
+11,038
New +$148K ﹤0.01% 3843
2019
Q4 		– Sell
-1,448
Closed -$16K – 3706
2019
Q3 		$16K Sell
1,448
-860
-37% -$19K ﹤0.01% 3666
2019
Q2 		$71K Buy
+2,308
New +$92.7K ﹤0.01% 3697

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Invesco's VRDN Position: Q2 2026 in Review

Invesco reduced its Viridian Therapeutics (VRDN) stake by 34% in Q2 2026, selling an estimated $833K and leaving 100,895 shares worth $1.85M. The position accounts for ﹤0.01% of the portfolio, ranked #2620.

Invesco first reported a position in VRDN in Q2 2019 and has held it in 19 quarters since. The position peaked at $5.71M in Q4 2025. 215 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Invesco held 100,895 shares of Viridian Therapeutics worth $1.85M as of Q2 2026.
  • Invesco sold 51,701 Viridian Therapeutics shares in Q2 2026, an estimated $833K.
  • Viridian Therapeutics made up ﹤0.01% of Invesco's portfolio in Q2 2026, its #2620 holding.
  • Invesco first reported a position in Viridian Therapeutics in Q2 2019 and has held it in 19 quarters since.
  • Invesco's Viridian Therapeutics position peaked at $5.71M in Q4 2025.
  • 215 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.